Voyager Therapeutics Inc (MEX:VYGR)
MXN 165 0 (0%) Market Cap: 6.53 Bil Enterprise Value: 325.05 Mil PE Ratio: 8.89 PB Ratio: 0.95 GF Score: 75/100

Voyager Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 05:45PM GMT
Release Date Price: MXN148
Dave Praharaj

Good morning, and welcome to the 42nd Annual JPMorgan Healthcare Conference. My name is Dave Praharaj, and I'm part of the Healthcare Investment Banking team here at JPMorgan.

Today, I have the pleasure of introducing our speaker, Dr. Al Sandrock, CEO of Voyager Therapeutics. In terms of logistics, please reserve any questions for after the presentation as we will have time. With that, take it away, Al.

Alfred W. Sandrock
Voyager Therapeutics, Inc. - President, CEO & Director

Thank you very much. Thank you very much. Good morning, ladies and gentlemen, and it's my pleasure to tell you about Voyager and how we're defining neurogenetic medicines. What I'll be telling you about today is basically 4 things: our pipeline, which consists of a wholly owned pipeline as well as some partner programs in neurogenetic medicines with at least 4 IND filings this year and next year, potentially generating clinical data in 2025 and 2026.

I'll be telling you about our platform, focus on our TRACER-derived capsids. We believe this is a leading

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot